To test whether the substance-P antagonist CJ-11.974 is effective and safe as a single agent for the treatment of mild to moderate ulcerative colitis, and whether this treatment produces measureable changes in markers of inflammation in this patient population.
Showing the most recent 10 out of 945 publications